Omega Funds, a Boston, MA-based investment firm focused on backing companies delivering impactful medicines to patients, closed Omega Fund VI, L.P., with $438 million in capital commitments.
With Fund VI, the firm will continue to execute on its strategy of creating and investing in life sciences companies that target the most urgent medical needs. Since its inception in 2004, Omega Funds has raised more than $1 billion to invest in exceptional entrepreneurs developing innovative products across multiple therapeutic areas, including:
– rare diseases,
– precision medicine, and
Led by Otello Stampacchia, Ph.D., Managing Director, Deirdre Cunnane, J.D., Chief Operating Officer and General Counsel, Paulina Hill, Ph.D., Principal, and Katie Kerfoot, head of Investor Relations, Fund VI is stage-agnostic and is expected to be deployed across companies in the U.S. and Europe. Similar to past funds, investments will include a variety of investment approaches, from company founding and creation to early venture rounds and late-stage public investing, as well as direct secondary transactions.
So far, Omega Funds’ portfolio companies have brought 37 new products to market and the firm’s investments have contributed to 24 portfolio company IPOs and 35 portfolio company exits via M&A.
Omega Funds also announced today that industry veteran Bernard Davitian will be joining the firm as a Partner, beginning January 2020.